At a glance
ClinicalIndex Comparison Record- ✓Age >18 years
- ✓Clinically diagnosed metastatic RCC
- ✓Treated with sunitinib as first-line therapy
- ✓Turkish citizenship
- ✕Treatment initiated but patient excluded from follow-up for any reason
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Retrospective Registry Based Study for Evaluating Treatment Response in Patients Targeted Treated With Metastatic Renal Cell Carcinoma (mRCC) With Sunitinib in First-line Therapy
In Brief
An observational study evaluating Sunitinib for Carcinoma, Renal Cell and Clear-cell Metastatic Renal Cell Carcinoma. Completed, enrolled 376 participants across 1 site.
Detailed Summary
The purpose of this study is to understand how patients with mRCC respond to the study medicine (called sunitinib) when they receive it as the first line of treatment after finding out the cause for the disease. This study will look into how different and how well groups of people with high chances of developing the disease respond to the study medicine. All data for this study will be anonymously extracted from data already entered in RCC Registry which is owned by Turkish Oncology Group Association (TOGD). This study will pull out records from the Registry between 01-Mar-2019 and 30-Oct-2022 that belongs to people: * who are Turkish citizens * who are older than 18 years * who were found out to have mRCC * who received sunitinib as the first line treatment after finding out the cause for the disease This study will look at the responses, experiences and how long the patients use the study medicine sunitinib.
Study Details
Timeline
Interventions
as provided in real world practice